I really don't understand your response to my very simple point. I've been in CTSO for 8+ years and I've accumulated a very large share count. I don't "trade" it because this type of stock can triple overnight. My point is that thinly traded, speculative biotechs like this absolutely do NOT trade based on classical technical parameters or even fundamentals. I was amused by the ridiculous chatter over the irrelevant "success fee" from a few months ago, much as I'm amused at the quarterly perseveration about sales data. What matters in this type of stock is the potential for massive success, and that's it. And yes, this can triple overnight. It can also go to zero overnight. I think the former is more likely at some point, perhaps sooner than you think. No chart or support level can predict a doubling or tripling overnight, but that's what happens when some of this massive potential is realized or becomes imminent in people's minds. If we were to see a partnership with one of the CAR-T cell pharma companies, I believe this would at least double and perhaps triple overnight or soon thereafter. No chart would be helpful in guiding to that determination. It's the odds of massive potential and a very low current market cap and NOT classical technical analysis that guides share price in these instances. Anything else, although perhaps well-intentioned, is superfluous noise and at least for me, irritating to wade through on a regular basis while looking for substantive posts. That's it.
Market Data 
Markets 
AI
